Genetic Signatures Limited Stock

Equities

GSS

AU000000GSS4

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. 01:13:32 2024-05-30 am EDT 5-day change 1st Jan Change
0.73 AUD -.--% Intraday chart for Genetic Signatures Limited +1.39% +67.82%
Sales 2024 * 10.1M 6.71M Sales 2025 * 26.2M 17.42M Capitalization 136M 90.52M
Net income 2024 * -17M -11.3M Net income 2025 * -6M -3.99M EV / Sales 2024 * 11.5 x
Net cash position 2024 * 20M 13.3M Net cash position 2025 * 7M 4.65M EV / Sales 2025 * 4.93 x
P/E ratio 2024 *
-7.77 x
P/E ratio 2025 *
-20.3 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 72.1%
More Fundamentals * Assessed data
Dynamic Chart
1 week+1.39%
1 month+3.55%
3 months+12.31%
6 months+40.38%
Current year+67.82%
More quotes
1 week
0.73
Extreme 0.725
0.77
1 month
0.61
Extreme 0.605
0.78
Current year
0.41
Extreme 0.405
0.78
1 year
0.38
Extreme 0.38
0.78
3 years
0.38
Extreme 0.38
1.86
5 years
0.38
Extreme 0.38
2.94
10 years
0.24
Extreme 0.235
2.94
More quotes
Managers TitleAgeSince
Director of Finance/CFO - 23-06-25
Chief Tech/Sci/R&D Officer - 01-02-14
Director/Board Member 64 14-01-01
Members of the board TitleAgeSince
Director/Board Member - 15-09-14
Director/Board Member - 22-05-12
Director/Board Member 64 14-01-01
More insiders
Date Price Change Volume
24-05-30 0.73 -.--% 94,057
24-05-29 0.73 +1.39% 143,571
24-05-28 0.72 +4.35% 77,328

Delayed Quote Australian S.E., May 30, 2024 at 01:13 am EDT

More quotes
Genetic Signatures Limited is an Australia-based specialist molecular diagnostics (MDx) company. The Company's principal activities include research and commercialization of identifying individual genetic signatures to identify diseases and the sale of associated products into the diagnostic and research marketplaces. The Company is focused on the development and commercialization of its platform technology, 3base. Its MDx 3base platform technology provides high-volume hospitals and pathology laboratories with the ability to screen for an array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. It designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen brand. Its products include EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, EasyScreen Viral Meningitis Detection Kit, and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.73 AUD
Average target price
0.75 AUD
Spread / Average Target
+2.74%
Consensus